Patient-derived xenografts and in vitro model show rationale for imatinib mesylate repurposing in HEY1-NCoA2-driven mesenchymal chondrosarcoma

Laboratory Investigation - Tập 102 - Trang 1038-1049 - 2022
Polona Safaric Tepes1,2, Danilo Segovia1,3, Sania Jevtic4, Daniel Ramirez5, Scott K. Lyons1, Raffaella Sordella1
1Cold Spring Harbor Laboratory, 1 Bungtown Road, 11724, Cold Spring Harbor, NY, USA
2Faculty of Pharmacy, University of Ljubljana, Kongresni trg 12, 1000, Ljubljana, Slovenia
3Graduate Program in Molecular and Cellular Biology, Stony Brook University, 100 Nicolls Rd, 11794, Stony Brook, NY, USA
4Phytoform Labs Ltd., Lawes Open Innovation Hub, West Common, Harpenden, Hertfordshire, England, UK
5Hospital for Special Surgery, Pathology and Laboratory Medicine, 535 E 70th St, 10021, New York, NY, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Laboratory Investigation

Tập 102

1038-1049

Thông tin tác giả